1. Home
  2. HEPA

HEPA

Hepion Pharmaceuticals Inc.

Logo Hepion Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Founded: N/A Country:
United States
United States
Employees: N/A City: EDISON
Market Cap: 9.9M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 77.7K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -12.50 EPS Growth: N/A
52 Week Low/High: $1.49 - $20.66 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: